Oregon Public Employees Retirement Fund Grows Stock Holdings in DexCom, Inc. $DXCM

Oregon Public Employees Retirement Fund grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 32.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,805 shares of the medical device company’s stock after acquiring an additional 10,979 shares during the period. Oregon Public Employees Retirement Fund’s holdings in DexCom were worth $3,015,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Andra AP fonden bought a new stake in shares of DexCom during the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom during the 2nd quarter valued at about $26,000. SJS Investment Consulting Inc. increased its position in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the period. Financial Consulate Inc. purchased a new stake in shares of DexCom in the third quarter worth about $29,000. Finally, Sound Income Strategies LLC boosted its position in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 285 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on DXCM. BTIG Research decreased their target price on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Morgan Stanley raised shares of DexCom from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $63.00 to $75.00 in a report on Tuesday, December 2nd. Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. TD Cowen reduced their target price on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Finally, Evercore ISI started coverage on DexCom in a research note on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average price target of $86.70.

DexCom Stock Down 1.5%

DXCM opened at $67.40 on Monday. The business’s fifty day simple moving average is $63.92 and its 200 day simple moving average is $72.00. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The stock has a market cap of $26.29 billion, a PE ratio of 37.44, a P/E/G ratio of 1.21 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach purchased 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 7,866 shares of company stock valued at $448,177 over the last quarter. 0.32% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.